Group 1 - Zhongke Lanyun expects a net profit of 1.4 billion to 1.43 billion yuan for 2025, representing a year-on-year increase of 366.51% to 376.51% due to significant gains from investments in Moer Thread and Muxi shares [1] - Chuanjinnuo anticipates a net profit of 430 million to 480 million yuan for 2025, reflecting a year-on-year growth of 144.24% to 172.64% [2] - Guangqi Technology signed contracts for mass production of metamaterials totaling 264 million yuan with four clients [4] Group 2 - Daqin Railway reported a cumulative freight volume of 390 million tons for 2025, a decrease of 0.54% year-on-year [5] - Nanjing Panda clarified that it has no related business in the brain-computer interface sector and has not generated any sales revenue from it [6] - Tianhe Magnetic Materials announced that shareholder Nantong Yuanlong plans to reduce its stake by up to 3% [7] Group 3 - Yili Group's chairman plans to reduce his stake by up to 0.98% within a specified timeframe [12] - Ankai Bus reported a 46.8% year-on-year increase in bus sales for 2025, with total sales reaching 8,569 units [13] - Giant Star Agriculture reported a December 2025 pig sales volume of 666,400 heads, a year-on-year increase of 118.23% [22] Group 4 - China Nuclear Power's cumulative commercial power generation for 2025 is expected to grow by 12.98% year-on-year, reaching 244.43 billion kWh [38] - Weili Medical anticipates a net profit of 75 million to 95 million yuan for 2025, a decrease of 66% to 57% year-on-year [39] - Aonong Biological reported a December 2025 pig sales volume of 162,300 heads, a year-on-year increase of 28.39% [40]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation for its active pharmaceutical ingredient, Apalutamide, which is used in the treatment of prostate cancer [1] Group 1 - Apalutamide is a non-steroidal anti-androgen drug that works by inhibiting the androgen receptor signaling pathway to delay disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1] - Apalutamide is to be used in conjunction with castration therapy under medical guidance [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation (CDE) for the active pharmaceutical ingredient (API) Apalutamide, which is used in the treatment of prostate cancer [1] Group 1 - Apalutamide is a non-steroidal anti-androgen drug that works by inhibiting the androgen receptor signaling pathway to slow disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1] - Apalutamide is intended to be used in combination with androgen deprivation therapy under the guidance of a physician [1]

Group 1 - The core point of the article is that Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation (CDE) for the active pharmaceutical ingredient Apalutamide [1] - Apalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer, functioning by inhibiting the androgen receptor signaling pathway to delay disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and it is to be used in conjunction with castration therapy under medical guidance [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Jingsheng Pharmaceutical, has recently passed the review by the National Medical Products Administration (NMPA) for the active pharmaceutical ingredient (API) Apalutamide, which is used in the treatment of prostate cancer [1] Group 1: Product Information - Apalutamide is a non-steroidal anti-androgen drug that works by inhibiting the androgen receptor signaling pathway to slow disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) [1] - Apalutamide is intended to be used in conjunction with androgen deprivation therapy under the guidance of a physician [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Jingsheng Pharmaceutical, has recently passed the CDE review for the active pharmaceutical ingredient (API) Apalutamide, which is used for the treatment of prostate cancer [1] Group 1: Regulatory Approval - The API Apalutamide has a packaging specification of 25 kg per barrel and is registered under the number Y20240000773 [1] - The company submitted the registration application in 2024, which has been accepted [1] - The API must obtain a "compliant" public notice from the Zhejiang Provincial Drug Administration for GMP conformity inspection before it can be marketed domestically [1] Group 2: Market Competition - As of the announcement date, there are 10 other manufacturers in China that have passed the technical review for the same API [1] - Jingsheng Pharmaceutical is currently preparing to apply for the GMP conformity inspection, indicating that the timeline for market entry remains uncertain [1]